FDA approves weight-loss drug, Zepbound, to treat sleep disorder - Peoples Gazette

FDA approves Eli Lilly's Zepbound for treating moderate to severe obstructive sleep apnea in obese patients, to be used with a reduced-calorie diet and increased physical activity. Clinical trials showed improved sleep apnea symptoms, and the drug's active ingredient, tirzepatide, is also effective for weight reduction.